OpenAI introduces GPT-Rosalind, its drug discovery AI - pharmaphorum

OpenAI has introduced GPT-Rosalind, a frontier reasoning model designed for drug discovery and biology research. The company stated it is the first release in its Life Sciences model series and is already working with partners including Amgen and Moderna. The model is named after Rosalind Franklin, the scientist whose work contributed to understanding DNA structure.

GPT-Rosalind aims to accelerate drug discovery processes and support research in biological sciences. OpenAI announced the model through a release, highlighting its application in life sciences. The company has engaged pharmaceutical firms Amgen and Moderna as early partners for this initiative.

This development follows recent organizational changes at OpenAI, including the departure of Kevin Weil, who led the OpenAI for Science research initiative. The launch represents a new focused effort in applied AI for healthcare and biotechnology domains.